Friday, June 22, 2012

Genentech sets new target: Alzheimer's

(Full story requires San Francisco Business Times subscription.)
The South San Francisco-based biotech powerhouse has inked its second deal focused on Alzheimer’s disease, giving it a potential one-two punch against the main suspects in the debilitating brain disease. But the collaboration with Swiss biotech AC Immune SA, announced June 18, also signals how aggressively Genentech is pursuing neuroscience.
After nearly three decades of developing and selling blockbuster cancer-fighting drugs like Avastin, Herceptin and the recently approved Perjeta, Genentech expects to use its expertise in antibodies to treat neurodegenerative diseases.
“Our ambitions are to be equally known in neuroscience” as in cancer, said James Sabry, Genentech's vice president of partnering.

No comments:

Post a Comment